Overview
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Eligibility
Inclusion Criteria:
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-70 years of age.
- Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
- Eastern Cooperative Oncology Group (ECOG) 0 to 1.
- Life expectancy \> 3 months.
Exclusion Criteria:
- The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.